N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012130), on August 18, 2025, and is solely responsible for the information contained therein.